AVS Bio buys UK reagent supplier Biorbyt to expand biomaterials catalog
What's the deal? AVS BioDealroom has a profile for this one. Try Dealroom → has acquired BiorbytDealroom has a profile for this one. Try Dealroom →, a Cambridge, UK-based supplier of antibodies, proteins, and other bio-reagents for life science research. The deal value was undisclosed. AVS Bio is a portfolio company of Washington, D.C.-area private investment firm Arlington Capital PartnersDealroom has a profile for this one. Try Dealroom →.
What each side brings: AVS Bio supplies critical inputs and services for the bioprocessing and biologics industries. Founded in 2011, Biorbyt sells more than 1 million SKUs — including antibodies, recombinant proteins, ELISA kits, and molecular biology reagents — through an ecommerce platform serving pharma, biotech, and academic customers.
What's the endgame? Arlington and AVS Bio want to build a scaled, diversified biomaterials provider. Biorbyt adds both product breadth and digital commerce capabilities to the platform.
What changes for customers? Biorbyt will keep operating under its existing leadership as part of AVS Bio, giving customers access to a wider catalog through a single channel.
"Biorbyt is highly complementary to AVS Bio's capabilities and will materially broaden its product offering while adding digital commerce capabilities," said Malcolm Little, a partner at Arlington Capital Partners.
The signal: The deal reflects continued consolidation in life science tools, as buyers assemble broad reagent catalogs and ecommerce reach to serve research customers across pharma, biotech, and academia through fewer suppliers.
Read more: finance.minyanville.com
Image credit: Generated with Gemini
